REFERENCES
- Fung-Tomc J, Dourgherty TJ, DeOrio FJ, Simich-Jacobson V, Kessler RE. Activity of cefepime against cef-tazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels. Antimicrob Agents Chemother 1989; 33: 498–502.
- Bauemfeind A, Schweighart S, Eberlein E, Jungwirth R. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE 2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin). Infection 1991; 19 (suppl. 5): 264-75.
- Hancock RE, Bellido F. Factors involved in the enhanced efficacy against Gram-negative bacteria of fourth-generation cephalosporins. J Antimicrob Chemother 1992; 29 (suppl. A): 1-6.
- Kessler RE, Bies M, Buck RE, et al. Comparison of a new cephalosporin, BMY-28142, with other broad-spectrum beta-lactam antibiotics. Antimicrob Agents Chemother 1985; 27: 207–16.
- Ehrhardt AF, Sanders CC. Beta-lactam resistance among Enterobacter species. J Antimicrob Chemother 1993; 32 (suppl. B): 1-11.
- Gradelski E, Fung-Tomc J, Huczko E, Kessler RE. Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations. J Antimicrob Chemother 1993; 32 ( B): 75-80.
- Barbhaiya RH, Fourgue ST, Shyu WC, Papp EA, Pittman KA. High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine. Antimicrob Agents Chemother 1987; 31: 55–9.
- Barbhaiya RH, Fourgue ST, Gleason CR, et al. Safety, tolerance and pharmacokinetic evaluation of cefepime after administration of single intravenous doses. Antimicrob Agents Chemother 1990; 34: 1118–22.
- Barradel LB, Bryson HM. Cefepime: a review of its antibacterial activity, pharmacokinetic properties and thera-peutic use. Drugs 1994; 47 (3): 471–505.
- Neu CH, Chin N, Jules K, Labthavikul P. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin. J Antimicrob Chemother 1986; 17: 441–52.
- Tomatsu K, Ando S, Masuyoshi S, Hirano M, Miyaki T, Kawaguschi H. Antibacterial activity of BMY-28142, a novel broad spectrum cephalosporin. J Antibiot 1986; 39: 1584-91.
- Masuyoshi S, Hiraoka M, Buck RE, et al. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefunozam, cefotaxime and cefmenoxime. Drugs Exp Chin Res 1985; 15: 1–10.
- Sanders CC. Cefepime: the next generation? Clin Infect Dis 1993; 17: 369–79.
- Dombusch K, Mortsell E, Goransson E. In vitro activi-ty of cefepime, a new parenteral cephalosporin, against recent European blood isolates and in comparison with piperacillin/tazobactam. Chemotherapy 1990; 36: 259–67.
- Okamoto MP, Nakahiro RK, Chin A, Bedikian A, Gill MA. Cefepime: a new fourth- generation cephalosporin. Am J Hosp Pharm 1994; 51: 463–77.
- Barckow D, Schwigon CD. Cefepime versus cefotaxime in the treatment of lower respiratory tract infections. J Antimicrob Chemother 1993; 32 (suppl. B): 187-93.
- Leophonte P, Bertrand A, Nouvet G, et al. A compara-tive study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections. J Antimicrob Chemother 1993; 32 (suppl. B): 165-73.
- Giamarellou H. Clinical experience with the fourth generation cephalosporins. J Chemother 1996; 8 (suppl. 2): 91-104.